Health Care

IQVIA’s award‑winning analytics and patient‑support tech drives cost savings, quality gains, and value‑based care for payors and health systems.

Short‑sale alerts for Sartorius reveal AQR’s bearish view amid rising competition, patent cliffs, and pricing pressure, yet the company’s digital growth and strong cash flow offer resilience.

Fresenius SE & Co. KGaA completes full acquisition of mAbxience, boosting its biopharma platform, enhancing biosimilar quality, and positioning for rapid market entry.

Discover how Bayer’s $2.2 billion Ohio plant will boost U.S. production of oncology, cardiovascular, and renal drugs, create 600 jobs, and strengthen supply‑chain resilience.

UnitedHealth Group’s robust market presence and strategic focus on value‑based care & digital transformation drive strong earnings, resilience and investor confidence.

Pfizer’s new LITFULO vitiligo data, executive stock disclosures and Medicare pricing moves show how the pharma giant is expanding into dermatology, boosting transparency, and navigating tighter pricing rules for a competitive edge.

Johnson & Johnson’s Phase 3 results for ICOTYDE® show sustained clearance in difficult‑to‑treat scalp, genital and hand/foot psoriasis with no new safety signals, promising a durable, cost‑effective IL‑23 peptide therapy.

Investigative analysis of Fresenius Medical Care AG short‑sale filings reveals modest investor concerns amid regulatory shifts, margin compression risks, and untapped growth in digital health and emerging markets.

Danaher’s Form 3 filings reveal how senior execs hold stock, deferred‑comp shares, and options, aligning incentives with shareholder value and compliance.

Neuova Holding AG appoints Joe Ghiz and Shannon Basham to lead global expansion of its tinnitus‑treatment device, boosting market reach, reimbursement deals and patient access.